{"id":"https://openalex.org/W4365512249","doi":"https://doi.org/10.1158/1538-7445.am2023-ct133","title":"Abstract CT133: Trial in progress: a multicenter phase 1/1b dose escalation study of WTX-124 as a monotherapy and in combination with pembrolizumab in patients with selected advanced or metastatic solid tumors","display_name":"Abstract CT133: Trial in progress: a multicenter phase 1/1b dose escalation study of WTX-124 as a monotherapy and in combination with pembrolizumab in patients with selected advanced or metastatic solid tumors","publication_year":2023,"publication_date":"2023-04-14","ids":{"openalex":"https://openalex.org/W4365512249","doi":"https://doi.org/10.1158/1538-7445.am2023-ct133"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2023-ct133","doi":"https://doi.org/10.1158/1538-7445.am2023-ct133","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.am2023-ct133","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5091619007","display_name":"Ildefonso Rodriguez-Rivera","orcid":"https://orcid.org/0000-0001-9211-1768","observed_orcids":["https://orcid.org/0000-0001-9211-1768"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ildefonso Ismael Rodriguez-Rivera","raw_affiliation_strings":["1NEXT Oncology, San Antonio, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1NEXT Oncology, San Antonio, TX;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082674870","display_name":"Justin C. Moser","orcid":"https://orcid.org/0000-0002-0643-6759","observed_orcids":["https://orcid.org/0000-0002-0643-6759"]},"institutions":[{"id":"https://openalex.org/I4210130412","display_name":"HonorHealth","ror":"https://ror.org/03szbwj17","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210130412"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Justin C. Moser","raw_affiliation_strings":["2HonorHealth Research and Innovation Institute, Scottsdale, AZ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2HonorHealth Research and Innovation Institute, Scottsdale, AZ;","institution_ids":["https://openalex.org/I4210130412"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079022151","display_name":"Mateusz Opyrchal","orcid":"https://orcid.org/0000-0003-2454-7441","observed_orcids":["https://orcid.org/0000-0003-2454-7441"]},"institutions":[{"id":"https://openalex.org/I4390039234","display_name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center","ror":"https://ror.org/00g1d7b60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039234","https://openalex.org/I592451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mateusz Opyrchal","raw_affiliation_strings":["3Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN;","institution_ids":["https://openalex.org/I4390039234"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029588412","display_name":"Brendan D. Curti","orcid":"https://orcid.org/0000-0003-3948-2708","observed_orcids":["https://orcid.org/0000-0003-3948-2708"]},"institutions":[{"id":"https://openalex.org/I2801670537","display_name":"Providence Portland Medical Center","ror":"https://ror.org/015tmw922","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801670537","https://openalex.org/I4210160466","https://openalex.org/I94396219"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brendan Curti","raw_affiliation_strings":["4Providence Cancer Institute, Portland, OR;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Providence Cancer Institute, Portland, OR;","institution_ids":["https://openalex.org/I2801670537"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049071296","display_name":"Mehmet As\u0131m Bilen","orcid":"https://orcid.org/0000-0003-4003-1103","observed_orcids":["https://orcid.org/0000-0003-4003-1103"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]},{"id":"https://openalex.org/I4390039307","display_name":"Winship Cancer Institute","ror":"https://ror.org/02gars961","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I132943300","https://openalex.org/I150468666","https://openalex.org/I4390039307"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mehmet A. Bilen","raw_affiliation_strings":["5Winship Cancer Institute of Emory University, Atlanta, GA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Winship Cancer Institute of Emory University, Atlanta, GA;","institution_ids":["https://openalex.org/I150468666","https://openalex.org/I4390039307"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022989853","display_name":"Saero Park","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405263496","display_name":"Werewolf Therapeutics (United States)","ror":"https://ror.org/01wrd9933","country_code":"US","type":"company","lineage":["https://openalex.org/I4405263496"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Saero Park","raw_affiliation_strings":["6Werewolf Therapeutics Inc., Watertown, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Werewolf Therapeutics Inc., Watertown, MA","institution_ids":["https://openalex.org/I4405263496"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011345666","display_name":"Marissa Bruno","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405263496","display_name":"Werewolf Therapeutics (United States)","ror":"https://ror.org/01wrd9933","country_code":"US","type":"company","lineage":["https://openalex.org/I4405263496"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marissa Bruno","raw_affiliation_strings":["6Werewolf Therapeutics Inc., Watertown, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Werewolf Therapeutics Inc., Watertown, MA","institution_ids":["https://openalex.org/I4405263496"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046173491","display_name":"Paul Windt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405263496","display_name":"Werewolf Therapeutics (United States)","ror":"https://ror.org/01wrd9933","country_code":"US","type":"company","lineage":["https://openalex.org/I4405263496"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul Windt","raw_affiliation_strings":["6Werewolf Therapeutics Inc., Watertown, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Werewolf Therapeutics Inc., Watertown, MA","institution_ids":["https://openalex.org/I4405263496"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005038640","display_name":"Kulandayan K. Subramanian","orcid":"https://orcid.org/0000-0002-7750-0025","observed_orcids":["https://orcid.org/0000-0002-7750-0025"]},"institutions":[{"id":"https://openalex.org/I4405263496","display_name":"Werewolf Therapeutics (United States)","ror":"https://ror.org/01wrd9933","country_code":"US","type":"company","lineage":["https://openalex.org/I4405263496"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kulandayan K. Subramanian","raw_affiliation_strings":["6Werewolf Therapeutics Inc., Watertown, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Werewolf Therapeutics Inc., Watertown, MA","institution_ids":["https://openalex.org/I4405263496"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102747606","display_name":"Sameer S Chopra","orcid":"https://orcid.org/0000-0002-7969-0555","observed_orcids":["https://orcid.org/0000-0002-7969-0555"]},"institutions":[{"id":"https://openalex.org/I4405263496","display_name":"Werewolf Therapeutics (United States)","ror":"https://ror.org/01wrd9933","country_code":"US","type":"company","lineage":["https://openalex.org/I4405263496"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sameer S. Chopra","raw_affiliation_strings":["6Werewolf Therapeutics Inc., Watertown, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Werewolf Therapeutics Inc., Watertown, MA","institution_ids":["https://openalex.org/I4405263496"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5031926846","display_name":"RANDI E. ISAACS","orcid":"https://orcid.org/0000-0003-0433-8976","observed_orcids":["https://orcid.org/0000-0003-0433-8976"]},"institutions":[{"id":"https://openalex.org/I4405263496","display_name":"Werewolf Therapeutics (United States)","ror":"https://ror.org/01wrd9933","country_code":"US","type":"company","lineage":["https://openalex.org/I4405263496"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Randi Isaacs","raw_affiliation_strings":["6Werewolf Therapeutics Inc., Watertown, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Werewolf Therapeutics Inc., Watertown, MA","institution_ids":["https://openalex.org/I4405263496"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"83","issue":"8_Supplement","first_page":"CT133","last_page":"CT133"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9624000191688538,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9624000191688538,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.023399999365210533,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9589999914169312},{"id":"https://openalex.org/keywords/anti-pd-1-combination-therapy","display_name":"anti-PD-1 combination therapy","score":0.8330000042915344},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6690000295639038},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7580000162124634},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8830000162124634},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.8640000224113464},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.746999979019165},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.8220000267028809},{"id":"https://openalex.org/keywords/cytokine-toxicity","display_name":"cytokine toxicity","score":0.46399998664855957}],"concepts":[{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.6687811613082886},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6099224090576172},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5008242130279541},{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.49974894523620605},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.49042603373527527},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.47950631380081177},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.473423033952713},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4636157155036926},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3677695095539093},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.32755762338638306},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.31034278869628906},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.3065747022628784},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2374500334262848},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.17956483364105225}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2023-ct133","doi":"https://doi.org/10.1158/1538-7445.am2023-ct133","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.am2023-ct133","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4388075693","https://openalex.org/W4399662709","https://openalex.org/W4365512163","https://openalex.org/W4282944927","https://openalex.org/W4220767421","https://openalex.org/W3213880233","https://openalex.org/W4404053122","https://openalex.org/W4224274268","https://openalex.org/W4415899153","https://openalex.org/W4388071286"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"High-dose":[2],"recombinant":[3,184],"human":[4,134,142,185],"IL-2":[5,38,59,97,115],"(HD":[6],"IL-2)":[7],"is":[8,39,50,83,110,127,194,250,281,308,404],"an":[9,51,66],"FDA-approved":[10],"therapy":[11,249,335,356],"that":[12,125,314],"produces":[13],"durable":[14],"complete":[15],"remissions":[16],"in":[17,79,105,136,154,212,270,283,297,364,436,451,455],"a":[18,57,71,130,174,209,240,255,279,370,438,448],"subset":[19],"of":[20,36,56,103,132,165,178,205,276,295,372,396,445,467],"patients":[21,220,229,317,337,363,456],"with":[22,160,214,221,262,299,318,341,453,457],"advanced":[23,222,320,358,459],"or":[24,144,211,223,321,325,333,460],"metastatic":[25,224,322,461],"cutaneous":[26,323],"melanoma":[27,324,342],"and":[28,69,78,88,94,163,202,239,377,384,450,481],"renal":[29,326],"cell":[30,327],"carcinoma.":[31],"However,":[32],"the":[33,76,106,114,169,196,215,274,284,288,345,468],"clinical":[34],"benefit":[35],"HD":[37],"counterbalanced":[40],"by":[41,129,140,145],"life-threatening":[42],"toxicities":[43],"such":[44],"as":[45,208,278,447],"capillary":[46],"leak":[47],"syndrome.":[48],"WTX-124":[49,82,104,126,149,172,206,263,277,296,331,400,446],"engineered":[52],"cytokine":[53,116],"prodrug":[54],"composed":[55],"wild-type":[58],"fused":[60],"via":[61],"proprietary":[62],"cleavable":[63],"linkers":[64],"to":[65,70,85,91,112,117,181,219,310,329,344,352,390],"inactivation":[67],"domain":[68],"half-life":[72],"extension":[73],"domain.":[74],"In":[75,99,168],"circulation":[77],"normal":[80,141],"tissues,":[81],"designed":[84],"remain":[86],"inactive":[87],"not":[89,139],"bind":[90],"high-":[92],"(\u03b1\u03b2\u03b3)":[93],"intermediate-affinity":[95],"(\u03b2\u03b3)":[96],"receptors.":[98],"contrast,":[100],"proteolytic":[101],"activation":[102,164],"tumor":[107,158,241,379,382],"microenvironment":[108],"(TME)":[109],"expected":[111],"liberate":[113],"stimulate":[118],"antitumor":[119,152,203],"immune":[120,245],"responses.":[121],"Preclinical":[122],"data":[123],"show":[124],"activated":[128],"range":[131],"dissociated":[133],"tumors":[135,226,463],"vitro":[137],"but":[138,360],"cells":[143],"patient":[146],"serum.":[147],"Moreover,":[148],"demonstrates":[150],"potent":[151],"activity":[153,204],"multiple":[155,392],"murine":[156],"syngeneic":[157],"models":[159],"substantial":[161],"expansion":[162,307,365],"tumor-infiltrating":[166],"lymphocytes.":[167],"MC38":[170],"model,":[171],"has":[173],"large":[175],"therapeutic":[176],"window":[177],">19-fold":[179],"compared":[180],"~3-fold":[182],"for":[183,243,357,471],"IL-2.":[186],"Methods:":[187],"This":[188],"first-in-human,":[189],"open-label":[190],"phase":[191,440],"1/1b":[192,441],"trial":[193],"investigating":[195],"safety,":[197],"tolerability,":[198],"pharmacokinetics,":[199],"pharmacodynamics,":[200],"immunogenicity,":[201],"administered":[207,264],"monotherapy":[210,280,332,401,449],"combination":[213,298,334,347,452],"anti-PD-1":[216],"antibody":[217],"pembrolizumab":[218,300,454],"solid":[225,462],"(NCT05479812).":[227],"All":[228],"must":[230,366],"have":[231,367],"\u2265":[232],"1":[233],"measurable":[234],"lesion":[235],"per":[236,338],"RECIST":[237],"1.1":[238],"type":[242],"which":[244],"checkpoint":[246],"inhibitor":[247],"(ICI)":[248],"indicated.":[251],"Dose":[252,306],"escalation":[253,294,403,443],"uses":[254],"modified":[256],"toxicity":[257],"probability":[258],"interval-2":[259],"study":[260,289,444],"design":[261],"intravenously":[265],"(IV)":[266],"every":[267,303],"two":[268],"weeks":[269],"28-day":[271],"cycles.":[272],"If":[273],"safety":[275],"established":[282],"first":[285],"three":[286],"cohorts,":[287],"will":[290,315,387],"then":[291],"initiate":[292],"dose":[293,402,442],"400mg":[301],"IV":[302],"six":[304],"weeks.":[305],"anticipated":[309],"include":[311],"four":[312],"arms":[313],"enroll":[316],"either":[319],"carcinoma":[328],"receive":[330],"(N=20":[336],"arm).":[339],"Patients":[340],"assigned":[343],"WTX-124/pembrolizumab":[346],"arm":[348],"may":[349],"be":[350,388],"na\u00efve":[351],"all":[353,361],"prior":[354],"systemic":[355],"disease,":[359],"other":[362],"previously":[368],"received":[369],"standard":[371],"care":[373],"ICI":[374],"regimen.":[375],"Pre-":[376],"on-treatment":[378],"biopsies,":[380],"archival":[381],"tissue,":[383],"blood":[385],"samples":[386],"used":[389],"investigate":[391],"exploratory":[393],"biomarkers.":[394],"As":[395],"January":[397],"12,":[398],"2023,":[399],"proceeding.":[405],"Citation":[406],"Format:":[407],"Ildefonso":[408],"Ismael":[409],"Rodriguez-Rivera,":[410],"Justin":[411],"C.":[412],"Moser,":[413],"Mateusz":[414],"Opyrchal,":[415],"Brendan":[416],"Curti,":[417],"Mehmet":[418],"A.":[419],"Bilen,":[420],"Saero":[421],"Park,":[422],"Marissa":[423],"Bruno,":[424],"Paul":[425],"Windt,":[426],"Kulandayan":[427],"K.":[428],"Subramanian,":[429],"Sameer":[430],"S.":[431],"Chopra,":[432],"Randi":[433],"Isaacs.":[434],"Trial":[435],"progress:":[437],"multicenter":[439],"selected":[458],"[abstract].":[464],"In:":[465],"Proceedings":[466],"American":[469],"Association":[470],"Cancer":[472,492],"Research":[473],"Annual":[474],"Meeting":[475],"2023;":[476],"Part":[477],"2":[478],"(Clinical":[479],"Trials":[480],"Late-Breaking":[482],"Research);":[483],"2023":[484],"Apr":[485],"14-19;":[486],"Orlando,":[487],"FL.":[488],"Philadelphia":[489],"(PA):":[490],"AACR;":[491],"Res":[493],"2023;83(8_Suppl):Abstract":[494],"nr":[495],"CT133.":[496]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2023-04-15T00:00:00"}